This CME initiative is designed to meet the educational needs of medical oncologists, surgeons, ONS nurses, and other healthcare providers involved in the treatment of patients with breast cancer.
Breast Cancer
Joyce A. O'Shaughnessy, M.D. specializes in medical oncology with board certification in both internal medicine as well as medical oncology. She is a Diplomate of the American Board of Internal Medicine with subspecialty certification in medical oncology. Dr. O'Shaughnessy focuses on her practice and clinical research on breast-cancer treatment. She is Director of Breast Cancer Research and at Baylor-Sammons Cancer Center and chair of Breast Cancer Research for The US Oncology Network. | 1. | Review the cellular pathways that influence estrogen-receptor activity and resultant breast-cancer pathogenesis; | 2. | Discuss the mechanisms of action of CDK 4/6 inhibitors and the resultant anti-tumorigenic effects in hormone-positive breast cancer; |
| 3. | Assess the clinical trial data for both approved and investigational CDK 4/6 inhibitors for patients with HR+, HER2 negative advanced or metastatic breast cancer. |
| 1. | Review the cellular pathways that influence estrogen-receptor activity and resultant breast-cancer pathogenesis; |
| 2. | Discuss the mechanisms of action of CDK 4/6 inhibitors and the resultant anti-tumorigenic effects in hormone-positive breast cancer; |
| 3. | Assess the clinical trial data for both approved and investigational CDK 4/6 inhibitors for patients with HR+, HER2 negative advanced or metastatic breast cancer. |


| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |